Welcome to the 5th Macrophage-directed Therapies Summit
Capitalize on the Dynamic Plasticity of Macrophages Across Oncology, Autoimmunity & Inflammation
The spotlight is on macrophages due to their potential to provide a double-edged sword to fight oncology, autoimmunity and inflammation. Comprising up to 50% of tumor mass and playing a substantial role in tumor resistance, it is critical to optimize phenotypic modulation of macrophages, simultaneously unlocking optimal reprogramming in inflammatory disease.
The complexity of these innate cells creates unique targeting challenges but the 5th Macrophage-Directed Therapies Summit returned as the only forum to address bottlenecks in clinical translation, safety and heterogeneity to advance adoptive cell therapies, anti-CD47 and next-gen therapies from discovery and through the clinic
With 24+ expert speakers (including 14 new companies!) from Carisma Therapeutics, Shoreline Biosciences, Moderna, Boehringer Ingelheim, SIRPant and Macomics, we collaborated with this exclusive community to consolidate clinical progress, reviewed novel targets and turbocharged investment to capitalize on their potential and secure a successful future for macrophage-directed therapies.
2023 World-Class Speakers Included:
Chief Scientific Officer
Harvard Medical School
Professor of Pathology
UC San Diego
"The Macrophage-directed Therapies Summit is an outstanding conference that brings together leaders from all areas of macrophage biology and therapeutic development. It is an event that has helped advance our understanding of how to harness macrophages for the treatment of human disease"
Whitehead Fellow, Whitehead Institute
"Best macrophage congress in the industry"
Chief Operating Officer, Faron Pharmaceuticals
"The Macrophage-directed Therapies Summit is an outstanding focus meeting gathering both academic and industrial afficionados contributing to moving next generation immunotherapies to cancer patients"
Chief Scientific Officer, OSE Immunotherapeutics
Lecturer of Immunology, University of Surrey
“As our understanding of macrophage biology advances and new drug candidates enter clinical development, the macrophage summit represents a unique opportunity for pioneers in the field to share and learn from each other across preclinical, manufacturing and development functions”
Executive Vice President & Chief Medical Officer, Pionyr Immunotherapeutics